Unaudited Financials for the Q ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals reported standalone unaudited results for Q1 FY26, with revenue from operations at Rs 1,665.90 lakhs, down about 2.3% from Rs 1,704.54 lakhs in the same quarter last year. Total income stood at Rs 1,671.67 lakhs versus Rs 1,709.03 lakhs YoY. Profit before tax improved to Rs 33.87 lakhs from Rs 27.10 lakhs, and profit after tax rose sharply to Rs 22.33 lakhs from Rs 16.69 lakhs, a YoY jump of around 34%. EPS for the quarter came in at Rs 0.23 versus Rs 0.17 in Q1 FY25. The statutory auditor issued a limited review report with an unmodified opinion, and no subsidiaries exist so no consolidation is required. The company also announced a record date of September 18, 2025 for dividend eligibility, and will seek shareholder approval to continue related party transactions with Sandu Brothers Private Limited.
Mixed picture for shareholders — top-line dipped slightly YoY but profitability improved meaningfully, with PAT growing over 33% on better cost management. The dividend record date suggests an upcoming dividend payout, while the continued related party transactions with Sandu Brothers is something investors should watch at the AGM.